Evidence map›Paper›PMID 30984274›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2019

The Antioxidative Action of ZTP by Increasing Nrf2/ARE Signal Pathway.

Liang Yang, Bing Xu, Chunxu Yuan, Zhi Dai, Yong Wang, Qiongya Li, Qifan Yang, Nuomin Li, Hong Qing

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Liang YangSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Bing XuChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Shenzhen 518110, China.
Chunxu YuanSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Zhi DaiChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Shenzhen 518110, China.
Yong WangChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Shenzhen 518110, China.
Qiongya LiChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Shenzhen 518110, China.
Qifan YangSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Nuomin LiSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.ORCID 0000-0002-9393-6064
Hong QingSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.ORCID 0000-0003-2820-450X
Beijing Institute of Technology · CNChina Resources (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

So far, more than 25,000 brain diseases have been shown to be related to oxidative stress. Excessive free radicals and reactive oxygen species (ROS) can attack cells resulting in dysfunctional proteins, lipids, and nucleic acid, finally leading to imbalance of energy metabolism, cell death, gene mutation, and immune reaction. Therefore oxidative stress plays an important role in neuronal diseases. As a traditional Chinese medicine, Zhengtian Pill (ZTP) was reported to have the ability to reduce the blood viscosity of migraine model rats, with increased beta-endorphin, serotonin, adrenaline, and dopamine in brain tissue. Moreover ZTP can effectively accelerate blood circulation and attenuate blood coagulation. However, the molecular mechanisms of ZPT are still unclear. Through the behavioral test we found that ZTP can significantly improve depression-like behavior induced by LPS when rat was treated with ZTP (L 0.17 g/kg, M 0.34 g/kg, and H 0.7 g/kg) intraperitoneal injection once a day for 30 consecutive days. And ZTP can resist oxidative stress (>72 h) for a longer time. And ZTP can promote the levels of ATP and SOD and reduce the levels of ROS and MDA in the brain. At the same time, ZTP can have antioxidant stress through increasing the expression level of Nrf2/HO-1/P38. These results show that ZTP may be a potential antioxidant stress drug for variety of diseases associated with oxidative stress injury.

Identifiers

PMID30984274
PMCPMC6431467
OpenAlexW2921005664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.